Varenicline Tablet, Film Coated
Product Images NDC 51407-755

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 51407-755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

51407-755-56.jpg (51407 755 56)

51407-755-56.jpg (51407 755 56)
Label for Varenicline 0.5 mg film-coated tablets, containing 56 tablets per bottle. The label includes the NDC number 51407-755-56 and identifies the product as prescription only. It provides storage instructions, dosage guidance to see prescribing information, and cautions to keep out of reach of children. Marketed by GSMS, Incorporated in Camarillo, CA.*
FDA Label Image

51407-756-56.jpg (51407 756 56)

51407-756-56.jpg (51407 756 56)
Label for Varenicline 1 mg film-coated tablets, containing 56 tablets per container. The label displays NDC 51407-756-56 and states each tablet contains 1.71 mg varenicline tartrate equivalent to 1 mg varenicline free base. It includes storage instructions and a pharmacist dispensing notice. Marketed by GSMS, Incorporated.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A bar chart titled 'Continuous Abstinence, Weeks 9 through 12' comparing the efficacy of Varenicline 0.5 mg, Varenicline 1.0 mg, flexible dosing of Varenicline, Bupropion SR 150 mg twice daily, and placebo across five separate studies. The y-axis represents percentage abstinence from 0% to 60%. Each treatment group is shown with bars indicating the percentage of continuous abstinence during weeks 9 to 12, with error bars representing variability.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart titled 'Continuous Abstinence, Weeks 9 through 52' illustrating the percentage of subjects maintaining abstinence in various studies. The chart compares groups receiving Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Varenicline Flexible, Bupropion SR 150 mg BID, and placebo across five different studies. Error bars indicate variability for each group's abstinence rates over the specified period.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph comparing the percentage of continuous abstinent patients over time (in weeks) between Varenicline 1.0 mg twice daily and placebo groups. The x-axis shows nontreatment follow-up in weeks, and the y-axis shows percentage continuous abstinent, with data points for each group represented by solid and dashed lines respectively.*
FDA Label Image

Structure-1 (Structure 1)

Structure-1 (Structure 1)
Chemical structure diagram of varenicline, the active ingredient in the VARENICLINE tablets. The image depicts the molecular structure, including the bicyclic core with nitrogen atoms and a carboxylate-containing side chain, representing its chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.